CCAD Seed Funding Paves the Way for Promising Clinical Advancements in Neuroinflammation
Charleston, SC June 13, 2025 – New Vision Research is proud to recognize the success of 2013 Charleston Conference on Alzheimer’s Disease (CCAD) awardee, Dr. John Kauwe, whose CCAD seed funding has helped lay the foundation for a new generation of clinical-stage therapeutics. Dr. Kauwe, now President of BYU Hawaii and Co-founder of Halia Therapeutics.
Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience announced the completion of enrollment for its open-label Phase 2a clinical trial evaluating HT-6184 (Ofirnoflast) in patients with lower-risk Myelodysplastic Syndrome (MDS) who are refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESA).
“CCAD gave me the opportunity to take a chance on a novel idea. That early support changed the trajectory of my career,” said Dr. Kauwe. “The discovery enabled by that funding has now evolved into a clinical-stage program with the potential to impact patients suffering from serious inflammatory and neurodegenerative diseases.”
About New Vision Research: New Vision Research (NVR) is a private non-profit organization dedicated to transforming the way medical research is funded. NVR invests in early-career researchers with innovative ideas, fosters collaboration through conferences like the Charleston Conference on Alzheimer’s Disease, and supports emerging leaders in various research fields through its New Vision Research Scholar programs.
Media Contact:
Tara Coker / Marketing Coordinator
tcoker@newvisionresearch.org
843-610-5452
Share or print this page